Hibma, Jennifer E.
Zur, Arik A.
Castro, Richard A.
Wittwer, Matthias B.
Keizer, Ron J.
Yee, Sook Wah
Goswami, Srijib
Stocker, Sophie L.
Zhang, Xuexiang
Huang, Yong
Brett, Claire M.
Savic, Radojka M.
Giacomini, Kathleen M.
Funding for this research was provided by:
National Institutes of Health (GM61390, UL1 RR024131, GM07546)
Swisse National Science Foundation (PBBSP3-133384.)
Article History
First Online: 23 November 2015
Compliance and Ethical Standards
:
: This project was funded by the National Institutes of Health (NIH) Grant GM61390, and also by the NIH/National Center for Research Resources (NCRR), University of California, San Francisco (UCSF)—Clinical & Translational Science Institute (CTSI) Grant UL1 RR024131. Jennifer E. Hibma was funded by the National Research Service Award T32 GM07546 from the NIH, and by the Department of Clinical Pharmacy at UCSF. Matthias B. Wittwer was funded by the Swiss National Science Foundation’s grant for prospective researchers (PBBSP3-133384). The authors are solely responsible for the content and do not necessarily represent the official views of the NIH.
: Kathleen M. Giacomini, Sook Wah Yee, Xuexiang Zhang, and Yong Huang have declared the following conflicts of interest that might be relevant to the content of this manuscript: Kathleen M. Giacomini and Sook Wah Yee are co-founders of Apricity Therapeutics, which develops drugs that exploit membrane transporters to enhance their pharmacologic action. Kathleen M. Giacomini receives funds from several pharmaceutical companies (AstraZeneca, Pfizer, Sanofi-Aventis, and GlaxoSmithKline) for research in her laboratory. Xuexiang Zhang and Yong Huang are employees of Optivia Biotechnology Inc., a transporter contract research organization (CRO) company.Jennifer E. Hibma, Arik A. Zur, Richard A. Castro, Matthias B. Wittwer, Ron J. Keizer, Srijib Goswami, Sophie L. Stocker, Claire M. Brett, and Radojka M. Savic have no conflicts of interest that might be relevant to the content of this study.
: This analysis was approved by the Committee on Human Research (CHR), which is the Institutional Review Board (IRB) at UCSF, approval # 10-02578.